Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer

被引：0
|
作者：
M Gijsen
P King
T Perera
P Parker
B Larijani
A Harris
A Kong
机构：
[1] University of Oxford,Cancer Research UK
[2] Johnson & Johnson Pharmaceutical Research & Development,undefined
[3] London Research Institute,undefined
来源：
Breast Cancer Research | / 12卷
关键词：
Breast Cancer; Trastuzumab; Feedback Loop; Xenograft Model; Fluorescence Resonance Energy Transfer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer
    Fakih, Marwan G.
    ONCOLOGIST, 2018, 23 (04): : 474 - 477
  • [22] Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
    Li, Xin
    Xu, Yuxiu
    Ding, Yun
    Li, Changfei
    Zhao, Hong
    Wang, Jiandong
    Meng, Songdong
    MOLECULAR CANCER, 2018, 17
  • [23] Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
    Xin Li
    Yuxiu Xu
    Yun Ding
    Changfei Li
    Hong Zhao
    Jiandong Wang
    Songdong Meng
    Molecular Cancer, 17
  • [24] Anthracycline-free therapy for HER2-amplified breast cancer
    Gennari, Alessandra
    Del Mastro, Lucia
    LANCET ONCOLOGY, 2013, 14 (11): : 1037 - 1038
  • [25] Trastuzumab in HER2-amplified or overexpressed gallbladder cancer: Experience from an Indian cancer center
    Mondal, D.
    Ganguly, S.
    Ghosh, J.
    Pandey, P.
    Roy, S.
    Biswas, B.
    ANNALS OF ONCOLOGY, 2022, 33 (08) : S1389 - S1389
  • [26] Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: to continue or not to continue
    Butterbaugh, S. T.
    Patel, R.
    Romond, E. H.
    Mathew, A.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 3098 - 3099
  • [27] Sensitivity of HER2-amplified colorectal organotypic cancer spheroids at ex vivo resistance to panitumumab and trastuzumab.
    Kratz, Jeremy D.
    Zarling, Lucas
    Sunil, Aishwarya
    Rehman, Shujah
    Johnson, Katherine Anne
    Makkar, Sarbjeet K.
    Pasch, Cheri
    Lassen, Nicole
    Lemmon, Kayla
    Clipson, Linda
    Lubner, Sam Joseph
    Skala, Melissa C.
    Deming, Dustin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [28] Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer
    Singer, C. F.
    Tan, Y. Y.
    Fitzal, F.
    Steger, G. G.
    Egle, D.
    Reiner, A.
    Rudas, M.
    Gruber, C.
    Bartsch, R.
    Fridrik, M.
    Seifert, M.
    Exner, R.
    Balic, M.
    Bago-Horvath, Z.
    Filipits, M.
    Gnant, M.
    CANCER RESEARCH, 2017, 77
  • [29] The activation of YES1 leads to the acquired resistance to neratinib in HER2-amplified breast and lung cancers
    Yamamoto, Hiromasa
    Takeda, Tatsuaki
    Suzawa, Ken
    Tomida, Shuta
    Miyauchi, Shunsaku
    Araki, Kota
    Nakata, Kentaro
    Miura, Akihiro
    Shien, Tadahiko
    Kitamura, Yoshihisa
    Sendo, Toshiaki
    Toyooka, Shinichi
    CANCER RESEARCH, 2020, 80 (16)
  • [30] Ado-trastuzumab for the treatment of metastatic HER2-amplified breast cancer patients previously treated with pertuzumab
    Al Rabadi, L. S.
    Kaempf, A.
    Lim, J. Y.
    Saraceni, M. M.
    Savin, M. A.
    Mitri, Z. I.
    CANCER RESEARCH, 2019, 79 (04)
12345